DCZ0415
DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients[1].
Product Specifications
CAS Number
[2242470-43-3]
UNSPSC
12352005
Target
Apoptosis; NF-κB
Type
Reference compound
Related Pathways
Apoptosis; NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dcz0415.html
Purity
99.81
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
O=C1N(C2=CC=C(CC3=CC=NC=C3)C=C2)C(C4C5C(C6)C6C(C=C5)C14)=O
Molecular Formula
C23H20N2O2
Molecular Weight
356.42
References & Citations
[1]Wang Y, et al. A Small Molecule Inhibitor Targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2019 Nov 15. pii: canres.3987.2018.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
NF-κB
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
